Skip to main content
B

Bodyport

Provides a noninvasive cardiac scale that measures hemodynamic biomarkers, including fluid status and heart function, through sensors embedded in a standard-scale design. This at-home device delivers real-time data to clinical care teams, enabling timely interventions to prevent hospitalizations and improve management of chronic heart conditions.

San Francisco, United StatesFounded 2014222K+ followers
Updated 4 months ago

Funding

$15.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

BI
Funding rounds are not available yet.

Founders

Product

Problem

Managing chronic heart conditions requires frequent monitoring of hemodynamic biomarkers to enable timely interventions and prevent hospitalizations. Traditional methods for assessing heart function and fluid status often lack the convenience and accessibility needed for effective at-home monitoring.

Solution

Bodyport offers a noninvasive cardiac scale that measures hemodynamic biomarkers, including fluid status and heart function, through sensors embedded in a standard-scale design. The at-home device detects signals through a person’s feet in less than 30 seconds and transmits data to clinical care teams, providing a holistic, personalized assessment. The Bodyport Congestion Index, a measure of fluid status, and other key biomarkers augment weight tracking and patient symptoms, enabling timely interventions to prevent hospitalizations and improve management of chronic heart conditions. The integrated solution includes a clinical dashboard and personalized patient experience, giving both patients and their care teams comprehensive, actionable health insights.

Target Audience

The primary users are clinical care teams managing patients with chronic heart conditions, as well as patients themselves who require convenient at-home monitoring of their heart health.

Features

  • Noninvasive measurement of hemodynamic biomarkers via sensors embedded in a standard-scale design
  • Detection of signals through the feet in less than 30 seconds
  • Measurement of Bodyport Congestion Index, a measure of fluid status
  • Clinical dashboard for care teams to monitor patient status and receive alerts
  • Personalized patient experience to improve engagement and outcomes
This profile is AI-generated and may contain inaccuracies.